Policy & Regulation
IRLAB Therapeutics receives US patent allowance for Parkinson's drug candidate IRL1117
27 October 2026 - IRLAB Therapeutics AB (STO:IRLAB-A), a Swedish developer of new treatments for Parkinson's disease, said on Tuesday that it has received a Notice of Allowance from the US Patent...
Thor Medical signs three-year isotope supply agreement with Medicines Discovery Catapult
27 October 2026 - Thor Medical ASA (OSE:TRMED), a supplier of alpha-emitters for precision cancer treatment, said on Tuesday that it has signed a three-year supply agreement with Medicines Discovery C...
Enhertu wins EU approval for HER2-positive early breast cancer treatment
27 October 2026 - Biopharmaceutical company AstraZeneca plc (LSE/STO/NYSE: AZN) and its Japanese pharmaceutical partner Daiichi Sankyo (TYO: 4568) said on Tuesday that the European Commission has appr...
Riboscience reports Phase 1a/b overall survival data for ENPP1 inhibitor RBS2418
27 October 2026 - Clinical-stage biotechnology company Riboscience LLC announced on Monday the presentation of initial overall survival (OS) and immune activation data from the Phase 1a/b clinical tri...
Cumberland Pharmaceuticals to submit New Drug Application for ifetroban
27 October 2026 - US biopharmaceutical company Cumberland Pharmaceuticals Inc (Nasdaq: CPIX) announced on Monday that it plans to submit a New Drug Application (NDA) to the US Food and Drug Administra...
Innovent Biologics' sintilimab new indication application accepted for review by NMPA
26 October 2026 - China-based biopharmaceutical company Innovent Biologics (HKEX: 01801) said on Monday that the China National Medical Products Administration (NMPA) has accepted for review a new ind...